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ABSTRACT: Pneumonia, one of  infectious diseases, becomes a major health care problem in 
Indonesia. The inappropriateness use of  treatment can lead to greater unexpected health outcome 
and prolonged length of  stay. A lot of  research has proved that pharmacists, as a part of  health 
care professionals, has important role in assuring patients to get the most optimal treatment 
benefit. The aim of  this study is to identify the influence of  pharmaceutical care intervention 
in reducing the length of  stay of  inpatients community acquired pneumonia. This experimental 
study involved 32 subjects with community acquired pneumonia hospitalized without any other 
infection between 18th August and 31st December 2010. Subjects were divided into two groups, 
i.e. intervention and control group, by simple random sampling technique. Intervention group 
received pharmaceutical care services i.e. drug related problems identification and solving based on 
Pharmaceutical Care Network Europe Classification and therapy guideline. Both group received 
hospital standard care. The primary outcome of  this study was length of  stay. All subjects were 
followed until 31 December 2010. Most of  drug related problems identified in this study were 
classified as treatment effectiveness (intervention group 76.19% and control group 81.82%) and 
treatment cost (intervention group 23.81% and control group 18.18%). Inappropriate use of  
antibiotic was the main cause for this drug related problems based on the pneumonia guideline. 
Ceftriaxone and ciprofloxacin (28.21%) were the most inappropriate used antibiotics found in 
this study. The mean of  length of  stay between intervention (6 days) and control group (8 days) 
was significantly different (P<0.05). Pharmaceutical care intervention significantly improved the 
length of  stay of  inpatients community acquired pneumonia.
Keywords: 
pharmaceutical 
care, intervention, 
community acquired 
pneumonia
*Corresponding Author:  Bobby Presley (Centre of Medicine Information & 
Pharmaceutical Care, Faculty of Pharmacy, University of Surabaya, Indonesia) 
email: bobbypresley@gmail.com
Article History:
Received: 5 Sep 2015         Accepted: 21 Sep 2015
Published:  1 Nov 2015         Available online: 13 Jan 2016
Jurnal  Sains  Farmasi  & Klini s ,  2 (1) ,  84-90
The Influence of Pharmaceutical Care Intervention 
on Inpatient Community Acquired Pneumonia: 
A Small Randomized Single Blind Study
B. Presley1*, I. Setiabudi2, Lestiono2 & Ediyono2
 1Centre of  Medicine Information & Pharmaceutical Care, Faculty of  Pharmacy, University of  Surabaya, Indonesia, 
2Faculty of  Pharmacy, University of  Surabaya, Indonesia
INTRODUCTION
Pneumonia is infectious disease categorized 
as one of  15 leading causes of  death in United 
State of  America in 2007, 2008, and 2009 [1]. In 
Indonesia according to Southeast Asian Medical 
Information Center/SEAMIC (2001), pneumonia 
was classified as the sixth leading caused of  death 
in Indonesia. In 2005, as much as 7071 children in 
Surabaya was diagnosed with pneumonia infection 
[2]. Pneumonia is an inflammatory infection on 
lung parenchyma that could be caused by bacteria, 
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virus, or fungi [3]. Pneumonia infection mostly 
caused by bacteria and Streptococcus pneumoniae 
and was count as the most causal pathogen for 
community acquired pneumonia other than 
Mycoplasma pneumoniae, Haemophilus influenzae, 
Legionella pneumoniae [3,4].   This result also 
reflected by study in 14 hospitals in Asian countries 
showed that Streptococcus pneumoniae (29.2%), 
Klebsiella pneumoniae (15.4%) and Haemophilus 
influenzae (15.1%) as the most causal pathogen 
found in community acquired pneumonia [5]. 
Antibiotics are the main and vital treatment 
in any infectious diseases including pneumonia. In 
spite of  massive development in drug including 
antibiotics, infectious diseases are still to be 
one of  most popular diseases in the world. The 
challenging issue in antibiotics treatment is to fight 
against antibiotic resistance that still happening 
until now. An ANSORP Study in 2004, resistance 
problem had emerged and reflected by the result 
among Streptococcus pneumoniae isolates showed 
that 52.4% were not susceptible to penicillin, 
23% were intermediate, and 29.4% were penicillin 
resistant [6]. This result also gave us information 
that choosing the appropriate antibiotic for each 
infection culprit is very important step to achieve 
optimal therapy. Antibiotics treatment should 
be considered after the diagnosis has been made. 
According to literatures, microbiological and 
susceptibility test should be done to choose the 
best antibiotic for the causal pathogen. Empirical 
antibiotic therapy usually applied, while waiting 
for the microbiology and susceptibility test result, 
based on the possible or most common local 
causal pathogen. Careful consideration should be 
used in choosing appropriate empirical therapy, 
because there were a greater risk of  developed 
antibiotics resistance and sub-optimal therapy due 
to inappropriate used of  antibiotic [7]. 
Globally, antibiotics have been classified as 
one of  the most frequently used drug, especially 
in low and developing countries including 
Indonesia. Ironically, this finding also followed by 
poor infection diagnosis [8]. This excessive use 
of  antibiotic might lead to many consequences 
such as high cost of  therapy, bacterial resistance, 
therapy failure, and drug interaction [9]. One 
observational study conducted in Turkey showed 
irrational used of  antibiotics in community was 40-
60%, while the rational used of  antibiotic in one of  
hospital was only 54.3% [10]. This study showed 
that risk of  inappropriate use of  antibiotics still 
high and need to be controlled. Antibiotics used 
control can be achieve by collaboration between 
healthcare professional in community and hospital 
setting. 
Pharmacists, as one of  the healthcare 
professional team, have an important role in 
optimizing medical therapy through pharmaceutical 
care which can lead to the improvement of  patient’s 
quality of  life. Pharmaceutical care concept was 
rising from the evolution of  pharmaceutical 
activity, especially regarding patient centered 
optimization of  drug used. Cipolle, Strand, and 
Morley defined pharmaceutical care as a practice 
in which the practitioner takes responsibility 
for a patient’s drug therapy needs, and is held 
accountable for this commitment [11]. According 
to Hepler and Strand, pharmaceutical care defined 
as the responsible provision of  drug therapy for the 
purpose of  achieving definite outcomes intended 
to improve a patient’s quality of  life [11,12]. Based 
on that definition the key point of  that concept is 
the shifting role of  pharmacist from drug oriented 
to patients oriented. This new concept has changed 
the role of  pharmacist including in Indonesia and 
stated in the standard of  pharmaceutical care in 
hospital (2004) and community (2006) [13]. 
The role of  pharmacist through 
pharmaceutical care is to optimize the benefit of  
pharmacotherapy by ensuring the outcomes to 
improve patient’s quality of  life [14]. The scope 
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of  pharmaceutical care include interaction inter-
healthcare professionals interaction, drug therapy 
monitoring, therapy recommendation, drug related 
problem, drug information and patients counseling 
[11,13]. Drug related problems analysis is part 
of  pharmaceutical care practice and become one 
of  the pharmacists’ role in hospital according to 
pharmaceutical care standard [13]. This study 
will focus on the impact of  pharmaceutical care 
intervention in reducing the length of  stay for 
community acquired pneumonia patients who was 
hospitalized in one of  private hospital in Indonesia.
METHODS
Study design
This study was prospective experimental 
design using 2 groups of  subjects, i.e: control and 
intervention groups.
Type of  subjects
Subjects were adult (>17 years old) inpatients 
diagnosed with community acquired pneumonia 
without any infectious disease other than 
community acquired pneumonia.
Type of  intervention
Intervention in this study is defined as drug 
related problem analysis using Pharmaceutical 
Care Network Europe 6.2 version as a tool. 
Therapy guideline used in this study is Infectious 
Diseases Society of  America/American Thoracic 
Society Consensus Guidelines on the Management 
of  Community-Acquired Pneumonia in Adults 
(2007)/(ATS guidelines).
Type of  outcomes
The main outcome is length of  stay. Length 
of  stay is calculated based on number of  days a 
patient was hospitalized.
Data collection
All patients in a private hospital who met 
inclusion criteria were included. Data collection was 
conducted from August 2010 to December 2010.
Data analysis 
Data in this study was presented on percentage 
of  each category. Data between control and 
intervention groups was compared with length of  
stay, then it were analyzed using SPSS 17th version 
and the Mann-Whitney test to see the association 
between pharmaceutical care intervention (drug 
related problem analysis) and reduced length 
of  stay. The p value ≤ 0.05 was considered as a 
statistical significance. 
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32 subjects met criteria inclusion
16 control 16 intervention
- Standard treatment - Standard treatment
- Drug related problem analysis
Drug related problem recommendation
 Outcome measure
Length of  stay
No drug related problem 
recommendation
Figure 1. Subject selection and data collection
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RESULTS & DISCUSSION
Results
A number of  44 subjects with community 
acquired pneumonia were collected from 18th 
August to 31st December 2010. 12 subjects were 
excluded because they had other infection disease 
like tuberculosis or HIV. Total of  32 subjects were 
used in this study and were divided into two groups 
using odd and event number, 16 patients in the 
control group and the rest in the intervention group.
Characteristic of  patients
The characteristic of  subjects is presented in table 1.
Types of  drug related problems
The types of  drug related problem is 
presented in table 2. Effect of  drug therapy not 
optimal was the types of  drug related problems 
that most commonly identified.
Drug related problems recommendation
Total drug related problems recommendation 
is presented in table 3.
Length of  stay
Reduction mean length of  stay in intervention 
group was found shorter than control group (6 
versus 8 days). Data analysis using Mann-Whitney 
test is presented in table 4.
Discussion
This study finding indicate that pharmaceutical 
care intervention by pharmacist could reduce 
mean length of  stay significantly in hospitalized 
patients with community acquired pneumonia.
Pharmaceutical care purpose is to improve 
patient’s quality of  life through optimization of  
drug therapy [11,12]. Pharmaceutical care could 
cover many scope and one of  them is drug related 
problems analysis by pharmacist. Therefore, the 
term of  pharmaceutical care intervention used 
in this study will focus on drug related problems 
analysis. Pharmaceutical Care Network Europe 
6.2 version tool was used to identify classification 
of  drug related problems. 
Based on the PCNE tool, this study found that 
most of  drug related problems were categorized 
on the treatment effectiveness (79.07%). Non-
optimal drug therapy was majority problems found 
in this study (62.79%), followed by unnecessary 
drug treatment (18.6%). Higher proportion 
in non-optimal therapy was primarily caused 
by inappropriateness of  antibiotic selection. 
Antibiotics therapy comparator in this study 
was antibiotics that were recommended by the 
Infectious Diseases Society of  America/American 
Thoracic Society Consensus Guidelines on the 
Management of  Community-Acquired Pneumonia 
in Adults. Ideally the choice of  antibiotic is based on 
definite diagnosis of  infection and microbiological 
test to choose the best and appropriate antibiotic 
based on the causal pathogen. But in practice 
one of  the obstacles was length of  time needs to 
get a microbiology test [7,15,16]. Based on that 
obstacle, empirical antibiotic therapy was used 
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Table 1.  Characteristic of  patients
Characteristic
Control group 
(n=16)
Intervention 
group (n=16)
Gender 
Male. (%)
Female. (%)
56.25 %
43.75 %
81.25 %
18.75 %
Age, Mean 
> 45
45-54
55-64
65-74
75-84
> 85
61.56
2
1
6
5
1
1
54.75
5
0
5
4
1
1
Compelling indication
Diabetes mellitus
Post CVA
Myelom tumour
Without compelling 
indication
1
1
1
13
1
1
0
14
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while waiting for microbiological test result. This 
study revealed that most of  antibiotic selection 
used was also the daily practice based on empirical 
therapy. DRP’s analysis will focus on the empirical 
therapy and not definite therapy because there is a 
habit to continue empiric antibiotic therapy until 
hospital discharge in patients who had a better 
condition with it.
Table 3.  Drug related problems recommendation
Recommendation Total Percentage (%)
Drug changes 17 85
Drug stoppage 3 15
Total 20 100
ATS guidelines indicate that the first line 
empirical therapy for community acquired 
pneumonia inpatient was using respiratory 
fluoroquinolone (levofloxacin, moxifloxacin, 
gemifloxacin) with level 1 recommendation 
or combination of  beta lactam (ceftriaxone, 
cefotaxime, or ampicillin sulbactam) and macrolide 
(azithromycin, clarithromycin) [16]. This study 
found most of  antibiotic used was combination 
of  ceftriaxone and ciprofloxacin (47.83%) and 
combination of  ceftriaxone and levofloxacin 
(26.09%). This finding also gave us information 
on antibiotic choice adherence to the guideline in 
clinical practice. This guideline was chosen because 
most of  clinician on this private hospital used it to 
treat the patients. Antibiotic combinations found in 
this study were not supported by strong evidence 
especially for community acquired pneumonia 
when compare to antibiotic choice in the guideline. 
Respiratory fluoroquinolone single therapy or 
combination of  beta lactam and macrolide were 
supported by many evidences. One of  the evidence 
was a meta-analysis of  randomized controlled 
trial by Konstantinoz et al stated that respiratory 
fluoroquinolone was equal to combination of  beta 
lactam and macrolide in mortality rate (2.7% vs 
3.4%), or in the treatment success (84.2% vs 82.2 
[17].
The mean length of  stay was shortened in 
the intervention group than control group (6 
days versus 8 days). According to study in Spain 
about factors that could influence length of  stay 
hospitalized patient with community acquired 
pneumonia found three factors (health care systems 
and hospital management, physician’s practices and 
skills, and patient’s characteristics). According to 
the study, choosing good proven clinical guideline, 
severity of  pneumonia, complication, and 
comorbidities will influence total length of  stay 
in patients with community acquired pneumonia 
[18]. Adherence to good proven clinical guideline 
in prescribing empirical antibiotic could also affect 
on patient’s length of  stay. This factor could be 
seen in study by Dambrava et al showed that 
adherence to guideline on empirical antibiotic 
selection have impact on mortality (3 versus 
10.6%) and mean length of  stay (7.6 versus 10.4 
days) between adherence group and not adherence 
group [19]. The appropriateness of  empirical 
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Table 2.  Details of  drug related problems
Primary 
domain
Problem Control Intervention Total Percentage (%)
Treatment 
effectiveness
Effect of  drug treatment not optimal 15 12 27 62.79
No effect of  drug treatment/ therapy failure 3 4 7 16.28
Treatment 
cost
Unnecessary drug-treatment 4 4 8 18.6
Drug treatment more costly than necessary - 1 1 2.33
Total 22 21 43 100
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antibiotic selection also give a benefit in the 
treatment effectiveness and length of  stay. One 
study compared levofloxacin and moxifloxacin in 
hospitalized patients with community acquired 
pneumonia reveal there is no significant difference 
in patient length of  stay (5.53 versus 5.61 days) 
with treatment consistency more higher in 
moxifloxacin than levofloxacin (81 versus 78.9%) 
[20]. In one of  meta analysis which comparing 
respiratory fluoroquinolone versus combination 
of  beta lactam and macrolide found that median 
length of  stay using respiratory fluoroquinolone 
were 1-2 days less than combination of  beta 
lactam and macrolide, but based on mean length 
of  stay there were no difference between those 
two [17]. Other study conducted by Frei et al 
comparing levofloxacin 750 mg versus ceftriaxone 
1000 mg and azithromycin 500mg daily showed 
there was 0.8 day reduction of  length of  stay 
and 1.2 days reduction of  length of  intravenous 
antibiotic therapy [21]. Although the result found 
significantly different in patient’s mean length of  
stay between groups, there was some limitation in 
this study, including: the inability to calculate the 
severity level of  pneumonia due to limitation of  
data to calculate severity index.
CONCLUSION
Pharmaceutical care intervention, defined 
as drug related problems analysis, could affect 
significantly in reducing mean length of  stay. 
Appropriateness use of  antibiotic was playing 
important role for the treatment effectiveness 
that also influenced patient’s length of  stay. This 
study could reflect the need of  pharmacist role 
in optimizing drug therapy management in the 
future.
The Influence of  Pharmaceutical Care Intervention on Inpatient…                 | Presley, et. al.
REFERENCES 
1.	 Kenneth	D,	 Kochanek	MA,	 Jiaquan	 X,	 	 Sherry	 L,	Murphy	 BS,	
Arialdi	M,	 	Miniño,	Hsiang-Ching	Kung.	National	Vital	Statistics	
Reports	 Deaths:	 Preliminary	 Data	 for	 2009	 National	 Vital	
Statistics	Reports;59(4).
2.	 Direktorat	 Jenderal	 Pemberantasan	 Penyakit	 Menular	 &	
Penyehatan	Lingkungan	(PPM	&	PL)	Departemen	Kesehatan	RI	
2004.		Angka	kematian	bayi	masih	tinggi	[internet].		[cited	2011	
November	 9].	 Available	 from:	 http://www.penyakitmenular.info/
pm/detil.asp?m=68s=2&i=240
3.	 Gelone	 SP,	 Donnell	 JO.	 Respiratory	 tract	 infections.	 In:	 Koda	
kimble,	MA,	Young	LY,	Alldredge	BK,	Corelli	RL,	Guglielmo	BJ,	
Kradjan	WA,	 editors.	 (2009).	 Applied	 therapeutics:	 the	 clinical	
use	of	the	drugs.	Maryland.	Lippincott	William	&	Wilkins:	p.60-7.
4.	 Clover	ML,	Reed	MD.	Lower	respiratory	tract	infections.	In:	Dipiro	
JT,	Talbert	RL,	Yee	GC,	Matzke,	Weels	BG,	Posey	LM.	(2008).	
Pharmacotherapy	 a	 pathophysiologic	 approach.7th	 ed.	 China:	
McGraw-Hill;	p.1768-77.
5.	 Song,	J.	H.,	Oh,	W.	S.,	Kang,	C.	I.,	Chung,	D.	R.,	Peck,	K.	R.,	
Ko,	 K.	 S.,	 ...	 &	 Kim,	 Y.	 S.	 (2008).	 Epidemiology	 and	 clinical	
outcomes	 of	 community-acquired	 pneumonia	 in	 adult	 patients	
in	 Asian	 countries:	 a	 prospective	 study	 by	 the	 Asian	 network	
for	 surveillance	 of	 resistant	 pathogens.	 International	 journal	 of	
antimicrobial	agents,	31(2),	107-114.
6.	 Song,	J.	H.,	Jung,	S.	I.,	Ko,	K.	S.,	Kim,	N.	Y.,	Son,	J.	S.,	Chang,	
H.	H.,	 ...	&	Lee,	N.	Y.	 (2004).	High	prevalence	of	antimicrobial	
resistance	 among	 clinical	 Streptococcus	 pneumoniae	 isolates	
in	 Asia	 (an	 ANSORP	 study).	 Antimicrobial	 agents	 and	
chemotherapy,	48(6),	2101-2107.	
7.	 Guglielmo	BJ.	Principles	of	infectious	diseases.	In:	Koda	kimble	
MA,	Young	LY,	Alldredge	BK,	Corelli	RL,	Guglielmo	BJ,	Kradjan	
WA,	editors.	(2009).	Applied	therapeutics:	the	clinical	use	of	the	
drugs.	Maryland:	Lippincott	William	&	Wilkins:	p.56.1.
8.	 INDONESIA:	 Antibiotic	 use	 "excessive",	 say	 specialists.	 IRIN	
[internet].	 2011	 April	 14	 [cited	 2012	 April	 20];	 available	 from:	
http://www.irinnews.org/Report/92475/INDONESIA-Antibiotic-
use-excessive-say-specialists
9.	 Ozkurt,	 Z.,	 Erol,	 S.,	 Kadanali,	 A.,	 Ertek,	 M.,	 Ozden,	 K.,	 &	
Tasyaran,	 M.	 A.	 (2005).	 Changes	 in	 antibiotic	 use,	 cost	 and	
consumption	 after	 an	 antibiotic	 restriction	 policy	 applied	 by	
infectious	 disease	 specialists.	 Japanese	 journal	 of	 infectious	
diseases,	58(6),	338-343.
10.	 Tunger,	 O.,	 Karakaya,	 Y.,	 Cetin,	 C.,	 Dinc,	 G.,	 &	 Borand,	 H.	
(2009).	 Rational	 antibiotic	 use.	 The	 Journal	 Of	 Infection	 In	
Developing	Countries,	3(2),	88-93.	.
11.	 Tan	 CK,	 Ahaditomo,	 Prayitno	 A.	 Pelaksanaan	 pelayanan	
farmasi	 kinis.	 In:	Aslam	M,	Tan	CK,	Prayitno	A,	 editors.	 2003.	
Farmasi	klinis	(Clinical	Pharmacy)	menuju	pengobatan	rasional	
dan	 penghargaan	 pilihan	 penderita.	 Jakarta:	 PT.	 Elex	 Media	
Komputindo.
Jurnal Sains Farmasi & Klinis | Vol. 02 No. 01 | November 2015 89
The Influence of  Pharmaceutical Care Intervention on Inpatient…                 | Presley, et. al.
12.	 Berenguer,	B.,	La	Casa,	C.,	de	La	Matta,	M.	J.,	&	Martin-Calero,	
M.	 J.	 (2004).	 Pharmaceutical	 care:	 past,	 present	 and	 future.	
Current	pharmaceutical	design,	10(31),	3931-3946.
13.	 Departemen	Kesehatan.	(2004).	Keputusan	Menteri	Kesehatan	
Republik	 Indonesia	 Nomor	 1197/Menkes/Sk/X/2004.	 Tentang	
Standar	Pelayanan	Farmasi	Di	Rumah	Sakit.
14.	 Dipiro	JT.	Encyclopedia	of	clinical	pharmacy.	(2003).	New	York:	
Marcel	Dekker.
15.	 Ahuja	D,	Britt	BB,	Bryan	CS.	 (2010).	Selection	of	antibiotics	 in	
critical	 care.	 In:	 Cunha,	 BA.	 Infectious	 disease	 in	 critical	 care	
medicine.	3rd	ed.	New	York:	Informa	healthcare;	P.487.		
16.	 Mandell,	 L.	 A.,	Wunderink,	 R.	 G.,	 Anzueto,	 A.,	 Bartlett,	 J.	 G.,	
Campbell,	G.	D.,	Dean,	N.	C.,	...	&	Torres,	A.	(2007).	Infectious	
Diseases	 Society	 of	 America/American	 Thoracic	 Society	
consensus	 guidelines	 on	 the	 management	 of	 community-
acquired	 pneumonia	 in	 adults.	 Clinical	 infectious	 diseases,	
44(Supplement	2),	S27-S72.	
17.	 Vardakas,	 K.	 Z.,	 Siempos,	 I.	 I.,	 Grammatikos,	 A.,	 Athanassa,	
Z.,	 Korbila,	 I.	 P.,	 &	 Falagas,	 M.	 E.	 (2008).	 Respiratory	
fluoroquinolones	 for	 the	 treatment	 of	 community-acquired	
pneumonia:	 a	 meta-analysis	 of	 randomized	 controlled	 trials.	
Canadian	Medical	Association	Journal,	179(12),	1269-1277.
18.	 Cabre,	M.,	Bolivar,	 I.,	Pera,	G.,	&	Pallares,	R.	 (2004).	Factors	
influencing	 length	 of	 hospital	 stay	 in	 community-acquired	
pneumonia:	 a	 study	 in	 27	 community	 hospitals.	 Epidemiology	
and	infection,	132(05),	821-829.
19.	 Dambrava,	P.	G.,	Torres,	A.,	Vallès,	X.,	Mensa,	J.,	Marcos,	M.	
A.,	Peñarroja,	G.,	 ...	&	Niederman,	M.	S.	(2008).	Adherence	to	
guidelines'	empirical	antibiotic	recommendations	and	community-
acquired	 pneumonia	 outcome.	 European	 Respiratory	 Journal,	
32(4),	892-901.
20.	 Friedman,	 H.,	 Song,	 X.,	 Crespi,	 S.,	 &	Navaratnam,	 P.	 (2009).	
Comparative	 Analysis	 of	 Length	 of	 Stay,	 Total	 Costs,	 and	
Treatment	 Success	 between	 Intravenous	Moxifloxacin	 400	mg	
and	 Levofloxacin	 750	 mg	 among	 Hospitalized	 Patients	 with	
Community-Acquired	Pneumonia.	Value	in	Health,	12(8),	1135-
1143.
21.	 Frei,	C.	R.,	Jaso,	T.	C.,	Mortensen,	E.	M.,	Restrepo,	M.	I.,	Raut,	
M.	K.,	Oramasionwu,	C.	U.,	 ...	 &	Mody,	S.	H.	 (2009).	Medical	
resource	 utilization	 among	 community-acquired	 pneumonia	
patients	 initially	 treated	 with	 levofloxacin	 750	 mg	 daily	 versus	
ceftriaxone	1000	mg	plus	azithromycin	500	mg	daily:	A	US-based	
study*.	Current	medical	research	and	opinion,	25(4),	859-868.
Jurnal Sains Farmasi & Klinis | Vol. 02 No. 01 | November 201590
